Education
About Us
Working with TipRanks
Follow Us
Disc Medicine, Inc. (IRON)
NASDAQ:IRON
IRON Stock Chart & Stats
$71.99
$0.74(1.19%)
At close: 4:00 PM EST
$71.99
$0.74(1.19%)
Day’s Range― - ―
52-Week Range$30.82 - $99.50
Previous CloseN/A
Volume41.94K
Average Volume (3M)476.89K
Market Cap
$2.72B
Enterprise Value$2.60B
Total Cash (Recent Filing)$615.92M
Total Debt (Recent Filing)$30.98M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Mar 27, 2026EPS Estimate
-1.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding37,750,160
10 Day Avg. Volume430,683
30 Day Avg. Volume476,891
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)3.95
Price to Sales (P/S)0.00
P/FCF Ratio-18.53
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-27.03K
Enterprise Value/Ebitda-16.05
Forecast
1Y Price Target
$123.44Price Target Upside71.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-6.72
Revenue Forecast (FY)$47.41M
Bulls Say, Bears Say
Bulls Say
Commercial PreparednessCompany has built commercial infrastructure with rare disease sales specialists, medical science liaisons, and field access staff to support patient treatment starts at priority accounts, indicating readiness for market launch.
Regulatory PathwayRegulatory alignment on using reductions in the biochemical marker PPIX as a surrogate endpoint supports a clearer path to accelerated approval for the oral therapy.
Safety ProfileExtensive Roche-derived safety data and prior development studies show no signal of abuse risk, reinforcing the drug's favorable safety profile for regulators and prescribers.
Bears Say
Clinical Efficacy RiskThe main trial did not show a statistically significant improvement in total pain-free time in sunlight, which could complicate the case for full approval.
Media-driven VolatilityMedia reports alleging external concerns about the drug's profile have triggered share selloffs and heightened perceived approval risk, amplifying investor uncertainty.
Regulatory Delay RiskAn extension of the accelerated review period due to potential concerns about efficacy and abuse potential increases the likelihood of a delayed decision and market volatility.
Disc Medicine News
IRON FAQ
What was Disc Medicine, Inc.’s price range in the past 12 months?
Disc Medicine, Inc. lowest stock price was $30.82 and its highest was $99.50 in the past 12 months.
What is Disc Medicine, Inc.’s market cap?
Disc Medicine, Inc.’s market cap is $2.72B.
When is Disc Medicine, Inc.’s upcoming earnings report date?
Disc Medicine, Inc.’s upcoming earnings report date is Mar 27, 2026 which is in 41 days.
How were Disc Medicine, Inc.’s earnings last quarter?
Disc Medicine, Inc. released its earnings results on Nov 06, 2025. The company reported -$1.77 earnings per share for the quarter, missing the consensus estimate of -$1.442 by -$0.328.
Is Disc Medicine, Inc. overvalued?
According to Wall Street analysts Disc Medicine, Inc.’s price is currently Undervalued.
Does Disc Medicine, Inc. pay dividends?
Disc Medicine, Inc. does not currently pay dividends.
What is Disc Medicine, Inc.’s EPS estimate?
Disc Medicine, Inc.’s EPS estimate is -1.75.
How many shares outstanding does Disc Medicine, Inc. have?
Disc Medicine, Inc. has 37,750,160 shares outstanding.
What happened to Disc Medicine, Inc.’s price movement after its last earnings report?
Disc Medicine, Inc. reported an EPS of -$1.77 in its last earnings report, missing expectations of -$1.442. Following the earnings report the stock price went down -1.483%.
Which hedge fund is a major shareholder of Disc Medicine, Inc.?
Currently, no hedge funds are holding shares in IRON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Disc Medicine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$123.44 (71.47% Upside)
$123.44 (71.47% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $16.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days <0.1%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.14%
12-Months-Change
Fundamentals
Return on Equity
-34.78%
Trailing 12-Months
Asset Growth
27.33%
Trailing 12-Months
Company Description
Disc Medicine, Inc.
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
IRON Stock 12 Month Forecast
Average Price Target
$123.44
▲(71.47% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Arcutis Biotherapeutics
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
9.74% Insiders
23.27% Mutual Funds
0.95% Other Institutional Investors
56.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---